| Acute bacterial skin and skin structure infection

Baxdela vs Kimyrsa

Side-by-side clinical, coverage, and cost comparison for acute bacterial skin and skin structure infection.

Deep comparison between: Baxdela vs Kimyrsa with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsKimyrsa has a higher rate of injection site reactions vs Baxdela based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Kimyrsa but not Baxdela, including UnitedHealthcare

Category

Baxdela

Kimyrsa

At A Glance

RouteIV infusion or Oral

FrequencyEvery 12 hours

ClassFluoroquinolone antibacterial

RouteIV infusion

FrequencySingle dose

ClassLipoglycopeptide antibacterial

Indications

Acute bacterial skin and skin structure infection
Community-Acquired Pneumonia

Acute bacterial skin and skin structure infection

Dosing

Acute bacterial skin and skin structure infection 300 mg IV infusion every 12 hours over 60 minutes, or 450 mg orally every 12 hours, for 5-14 days; IV dose reduced to 200 mg every 12 hours in patients with eGFR 15-29 mL/min/1.73m2.

Community-Acquired Pneumonia 300 mg IV infusion every 12 hours over 60 minutes, or 450 mg orally every 12 hours, for 5-10 days; IV dose reduced to 200 mg every 12 hours in patients with eGFR 15-29 mL/min/1.73m2.

Acute bacterial skin and skin structure infection 1,200 mg as a single dose by intravenous infusion over 1 hour in patients 18 years and older.

Contraindications

Known hypersensitivity to delafloxacin, any fluoroquinolone antibacterial, or any component of BAXDELA

Use of intravenous unfractionated heparin sodium for 120 hours (5 days) after KIMYRSA administration due to false aPTT elevation
Known hypersensitivity to oritavancin products

Drug Interactions

1299View drug interactions

971View drug interactions

Adverse Reactions

Most common (>=2%) Nausea, diarrhea, headache, transaminase elevations, vomiting

Serious Tendinitis and tendon rupture, peripheral neuropathy, CNS effects, hypersensitivity reactions, Clostridioides difficile-associated diarrhea, blood glucose disturbances

Most common (>=3%) Headache, nausea, vomiting, limb and subcutaneous abscesses, diarrhea

Serious Cellulitis, osteomyelitis, hypersensitivity reactions, infusion related reactions, Clostridioides difficile-associated diarrhea

Pharmacology

Delafloxacin is a fluoroquinolone antibacterial that inhibits bacterial topoisomerase IV and DNA gyrase, enzymes required for bacterial DNA replication, transcription, repair, and recombination, exhibiting concentration-dependent bactericidal activity against gram-positive and gram-negative organisms.

Oritavancin is a semisynthetic lipoglycopeptide antibacterial that exerts concentration-dependent bactericidal activity via three mechanisms: inhibition of cell wall transglycosylation and transpeptidation steps, and disruption of bacterial membrane integrity, active against Gram-positive organisms including methicillin-resistant S. aureus.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Baxdela